Iovance Biotherapeutics, Inc. (IOVA) has 20 bekannte Insider- und institutionelle Anteilseigner verzeichnet. Der größte Anteilseigner ist Hamilton Atlantic mit 20,960,016 Aktien. Weitere bedeutende Anteilseigner sind KESSLER PAUL und VOYTICKY DAVID J.
In den letzten 12 Monaten haben Insider 43 Transaktionen in IOVA Aktien getätigt — 15 Käufe (im Wert von $107.19K) und 0 Verkäufe (im Wert von RSU Award). Insider-Käufe haben die Verkäufe übertroffen, was auf Vertrauen in die Unternehmensaussichten hindeuten kann.
IOVA Insider-Beteiligungen
Größter Aktionär
Hamilton Atlantic
20,960,016 Aktien
Käufe (12 Monate)
15
$107.19K Wert
Verkäufe (12 Monate)
0
$0.00 Wert
12-Monats-Transaktionsaktivität
Top-Insider-Aktionäre
| # |
Name |
Funktion |
Gehaltene Aktien |
Zuletzt gemeldet |
Relative Größe |
| 1 |
Hamilton Atlantic |
10 Percent Owner |
20,960,016 |
2010-11-04 |
|
| 2 |
Kessler Paul |
Chair,ceo, Pres., PR.acctg |
15,693,215 |
2013-07-26 |
|
| 3 |
Voyticky David J |
Director |
13,353,215 |
2013-07-26 |
|
| 4 |
Brooke Robert T. |
Officer |
4,440,008 |
2011-04-13 |
|
| 5 |
Bristol Investment Fund Ltd |
10 Percent Owner |
3,867,863 |
2014-11-07 |
|
| 6 |
Cataldo Tony |
CEO, President |
3,000,000 |
2011-05-09 |
|
| 7 |
Ayer Capital Management, Lp |
10 Percent Owner |
2,823,333 |
2015-05-08 |
|
| 8 |
Singh Manish |
10 Percent Owner, Officer: President and CEO |
2,546,000 |
2014-01-22 |
|
| 9 |
Lewis Gerald |
10 Percent Owner, Officer: Secretary Tresurer |
2,000,000 |
2008-03-07 |
|
| 10 |
Abotaleb Ibrahim |
10 Percent Owner, Officer: President & CEO |
2,000,000 |
2008-03-07 |
|
| 11 |
Mckilligan Richard |
Officer |
1,220,016 |
2011-04-13 |
|
| 12 |
Schroeder Martin |
Director |
1,000,000 |
2012-03-09 |
|
| 13 |
Ahn Mark J |
Director |
750,000 |
2010-05-28 |
|
| 14 |
Schiffman Gregory T |
Chief Financial Officer |
300,000 |
2016-11-15 |
|
| 15 |
Hawkins Elma |
President & CEO |
275,000 |
2016-03-16 |
|
| 16 |
Fardis Maria |
President and CEO |
250,000 |
2021-01-06 |
|
| 17 |
Vogt Frederick G |
Interim CEO & General Counsel |
235,000 |
2026-03-11 |
|
| 18 |
Fischkoff Steven A. |
Chief Medical Officer |
225,000 |
2016-04-21 |
|
| 19 |
Lotze Michael |
Chief Scientific Officer |
225,000 |
2016-03-30 |
|
| 20 |
Henderson Molly |
CFO |
150,000 |
2016-06-15 |
|
Aktuelle Transaktionen (letzte 12 Monate)
| Datum |
Name |
Funktion |
Typ |
Aktien |
Kurs |
Wert |
| 2026-03-09 |
Kirby Daniel Gordon |
Chief Commercial Officer |
RSU-Zuteilung |
132,200 |
- |
- |
| 2026-03-09 |
Puri Raj K. |
Chief Regulatory Officer |
RSU-Zuteilung |
117,500 |
- |
- |
| 2026-03-09 |
Roche Corleen M. |
Chief Financial Officer |
RSU-Zuteilung |
132,200 |
- |
- |
| 2026-03-09 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
RSU-Zuteilung |
58,750 |
- |
- |
| 2026-03-09 |
Vogt Frederick G |
Interim CEO & General Counsel |
RSU-Zuteilung |
235,000 |
- |
- |
| 2026-03-09 |
Bilinsky Igor |
Chief Operating Officer |
RSU-Zuteilung |
117,500 |
- |
- |
| 2026-03-05 |
Puri Raj K. |
Chief Regulatory Officer |
Optionsausübung (Verkauf) |
39,059 |
- |
- |
| 2026-03-05 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
Optionsausübung (Verkauf) |
31,246 |
- |
- |
| 2026-03-05 |
Vogt Frederick G |
Interim CEO & General Counsel |
Optionsausübung (Verkauf) |
62,493 |
- |
- |
| 2026-03-05 |
Bilinsky Igor |
Chief Operating Officer |
Optionsausübung (Verkauf) |
31,246 |
- |
- |
| 2026-03-02 |
Puri Raj K. |
Chief Regulatory Officer |
Optionsausübung (Verkauf) |
5,470 |
- |
- |
| 2026-03-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
Optionsausübung (Verkauf) |
3,907 |
- |
- |
| 2026-03-02 |
Vogt Frederick G |
Interim CEO & General Counsel |
Optionsausübung (Verkauf) |
10,418 |
- |
- |
| 2026-03-02 |
Bilinsky Igor |
Chief Operating Officer |
Optionsausübung (Verkauf) |
3,517 |
- |
- |
| 2026-02-24 |
Kirby Daniel Gordon |
Chief Commercial Officer |
Optionsausübung (Verkauf) |
150,000 |
- |
- |
| 2026-02-10 |
Kirby Daniel Gordon |
Chief Commercial Officer |
RSU-Steuereinbehalt |
16,450 |
$2.60 |
$42.77K |
| 2025-12-01 |
Puri Raj K. |
Chief Regulatory Officer |
Optionsausübung (Verkauf) |
5,469 |
- |
- |
| 2025-12-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
Optionsausübung (Verkauf) |
3,906 |
- |
- |
| 2025-12-01 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
Optionsausübung (Verkauf) |
8,789 |
- |
- |
| 2025-12-02 |
Vogt Frederick G |
Interim CEO & General Counsel |
Optionsausübung (Verkauf) |
10,417 |
- |
- |
| 2025-12-01 |
Vogt Frederick G |
Interim CEO & General Counsel |
Optionsausübung (Verkauf) |
41,669 |
- |
- |
| 2025-12-02 |
Bilinsky Igor |
Chief Operating Officer |
Optionsausübung (Verkauf) |
3,516 |
- |
- |
| 2025-12-01 |
Bilinsky Igor |
Chief Operating Officer |
Optionsausübung (Verkauf) |
8,789 |
- |
- |
| 2025-09-02 |
Puri Raj K. |
Chief Regulatory Officer |
Optionsausübung (Verkauf) |
5,470 |
- |
- |
| 2025-09-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
Optionsausübung (Verkauf) |
3,907 |
- |
- |
